



## European Association for Haemophilia and Allied Disorders



4th Annual Congress

Programme and Abstracts

2–4 February 2011

Starling Geneva Hotel & Conference Center,  
Geneva, Switzerland

# European Association for Haemophilia and Allied Disorders 4th Annual Congress, Wednesday 2nd – Friday 4th February 2011 Geneva

## EAHAD Executive Committee

PM. Mannucci	President
J. Astermak	Vice-President
Ph. de Moerloose	Secretary
G. Dolan	Company Secretary
Ch. Ludlam	Past President
K. Fischer	
C. Harrington	
M. Makris	
Cl. Negrier	
J. Oldenburg	
I. Peake	

European Association for Haemophilia and Allied Disorders Ltd  
Limited Company registered in England No. 06373427  
Registered as a Charity in England No. 1125081

EAHAD Secretariat,  
City View House Union Street,  
Manchester, M12 4JD, UK

Financial assistance is gratefully acknowledged from

Baxter Healthcare SA  
Bayer Schering Pharma  
bioMérieux Suisse SA  
CSL Behring  
GlaxoSmithKline  
Hyphen BioMed / Endotell  
Inspiration Biopharmaceuticals  
Instrumentation Laboratory  
LFB  
Novo Nordisk  
Octapharma AG  
Pfizer Specialty Care Europe  
Roche Diagnostics  
Stago  
Swedish Orphan Biovitrum/Biogen Idec Hemophilia

## SYMPOSIA

### WEDNESDAY 2nd February, 2011

**Registration Opening Times** 13:00–19:00 (level -1 of the Hotel)

All sessions take place in the plenary room **Crans-Montana**, level -1 of the Hotel

**14:30–16:00**

*Swedish Orphan Biovitrum/Biogen Idec Hemophilia* Satellite Symposium

**Fc Technology in Hemophilia: An approach to prolonged protection**

Chairman: Professor Erik Berntorp (Sweden), Co-Chairman: Dr Stephen James (Sweden)

#### The Technology

14:30–14:40 Long-acting factor concentrates: Technical possibilities, Professor Erik Berntorp (Sweden)  
14:40–14:50 Fc fusion technology: Molecular and preclinical studies, Dr Glenn Pierce (US)  
14:50–15:00 Question and Panel Discussion

#### The Clinical Program

15:00–15:15 rFIXFc Phase I/IIa data and B-LONG Clinical Trial, Professor K. John Pasi (UK)  
15:15–15:30 rFVIII Fc Phase I/IIa data and A-LONG Clinical Trial, Associate Professor Neil C. Josephson (US)  
15:30–15:40 Regulatory authority guidelines for clinical documentation of FVIII and FIX, Jørgen Ingerslev (Denmark)  
15:40–16:00 Question and Panel Discussion

### WEDNESDAY 2nd February, 2011

**16:30–18:00**

*Bayer Schering Pharma* Satellite Symposium

#### The Future Outlook in Hemophilia

Chairman: Johannes Oldenburg (Germany)

16.30–16.35 **Welcome**  
J. Oldenburg  
16.35–16.55 **The Challenge of Managing New Co-Morbidities in an Ageing Hemophilia Population**  
E. Santagostino (Italy)  
16.55–17.15 **New Patient Care Opportunities Through Innovative Research**  
J. Mahlangu (South Africa)  
17.15–17.35 **Socioeconomic Aspects of Management: The Case for Additional Support**  
K. Steen Carlsson (Sweden)  
K. Berger (Germany)  
17.35–17.50 **Debating the Balance Between Components of Care**  
Moderated by J. Oldenburg  
17.50–18.00 **Discussion and Close**  
J. Oldenburg

WEDNESDAY 2nd February, 2011

18:30–20:00

*Pfizer* Satellite Symposium

**Managing Haemophilia for Life “Beta, gamma, delta”- Transitions in childhood and adolescence towards adulthood**

Chairmen: Pier Mannuccio Mannucci (Italy), Jan Astermark (Sweden)

Welcome and introduction

The challenges of transition, Elena Santagostino (Italy)

Case presentation of a transition, Pia Petrini (Sweden)

The case for the children’s hospital comprehensive care centre, Ri Liesner (UK)

The case for the comprehensive care centre with a children’s department, Robert Klamroth (Germany)

Discussion and debate

Summary and close, Pier Mannuccio Mannucci (Italy), Jan Astermark (Sweden)

THURSDAY, 3rd February, 2011

**Registration Opening Times** 07:00–18:00 (level -1 of the Hotel)

All sessions take place in the plenary room **Crans-Montana**, level -1 of the Hotel

07:45–09:30

*Baxter* Satellite Symposium

**Comprehensive Inhibitor Management from Start to Finish: Predict, Prevent and Treat**

07:45–07:55

Opening remarks. Armin Reiningger, Baxter Healthcare

07:55–08:15

Predict: Genetics of Inhibitors. Jan Astermark, (Sweden)

08:15–08:35

Prevent: Therapies that May Prevent Inhibitor Development.  
Günter Auerswald (Germany)

08:35–08:55

Treat: Immune Tolerance Induction – Eradicating Inhibitors.  
Charles Hay (UK)

08:55–09:15

Treat: Persistent Inhibitors – Optimal Therapy towards Joint Protection.  
Alessandro Gringeri (Italy)

09:15–09:30

Q&A. Armin Reiningger, Baxter Healthcare

## EAHAD CONGRESS

THURSDAY, 3rd February

Registration Opening Times 07:00–18:00 (level -1 of the Hotel)

All sessions take place in the plenary room **Crans-Montana**, level -1 of the Hotel

10:00–12:30

Introduction

Session 1

Ongoing studies

EUHASS

EAHAD working parties

SIPPET, RESIST

PedNet studies

EHTSB, ADVANCE

Ph. de Moerloose

Chairs: P.M. Mannucci,

C.A. Ludlam

M. Makris (UK)

J. Oldenburg, A. Federici,

F. Peyvandi (Germany  
and Italy)

A. Gringeri (Italy)

K. Fischer (Netherlands)

G. Dolan (UK)

12:30–14:00

Lunch

14:00–15:30

Session 2

Platelet disorders

Identification of new platelet phenotypes  
through phenotyping and targeted sequencing

Diagnostic assessment of macrothrombocytopenia  
and the place of MYH9 mutation screening

Management of inherited thrombocytopenias

Chairs: I. Peake, M. Makris

S. Watson (UK)

CL. Balduini (Italy)

T. Lecompte (France)

15:30–16:00

Break

16:00–17:30

Session 3

Rare bleeding disorders

Hereditary haemorrhagic telangiectasia

Acquired von Willebrand Syndrome (AVWS)

Does mild factor XI deficiency really cause  
bleeding?

Chairs: F. Peyvandi,

J. Oldenburg

L.M. Botella (Spain)

A.B. Federici (Italy)

U. Seligsohn (Israel)

17:30

General Assembly

19:00

Gala dinner at Ariana Museum

**FRIDAY, 4th February**

**Registration Opening Times 07:30–16:00** (level -1 of the Hotel)

All sessions take place in the plenary room **Crans-Montana**, level -1 of the Hotel

**8:00–10:00**

**Session 4**

**Haemophilic arthropathy**

**Chairs: J. Astermark,**

**J-F. Schved**

**AROSINIUS LECTURE:** Haemophilic arthropathy.

*E.C. Rodriguez-Merchan  
(Spain)*

Validation of three-dimensional gait analysis  
(3DGA) for the detection of infraclinical  
changes in hemophilic lower limb arthropathy

*S. Lobet (Belgium)*

**Debate**

Ankle replacement. Yes

*J. Asencio (France)*

Ankle replacement. No

*L. Solimeno (Italy)*

**10:00–10:30**

**Break**

**10:30–12:00**

**Session 5**

**Haemophilia and aging**

**Chairs: G. Dolan,**

**C. Negrier**

Population demographics in haemophilia  
Challenges to manage cardiovascular diseases in  
haemophilia  
Osteoporosis: a real problem in haemophilia?

*J. Windyga (Poland)*

*R.E. Schutgens*

*(Netherlands)*

*M. Khawaji (Sweden)*

**12:00–13:30**

**Lunch**

**12:15–13:15**

**Special Lectures**

**Chairs: E. Berntorp,**

**R. Lassila**

Erik von Willebrand – who was he?  
von Willebrand disease: recent history, current status  
and future prospects

*O. Lindberg (Finland)*

*D. Lillicrap (Canada)*

**13:30–14:30**

**Session 6**

**Women and children with bleeding**

**Chairs: C. Lee,**

**K. Fischer**

Menorrhagia in women with bleeding disorders  
Management of pregnancy in women with bleeding  
disorders

*F. Peyvandi (Italy)*

*R.A. Kadir (UK)*

**14:30–15:30**

**Debate**

**Delivery of a severe haemophilia fetus.**

**I. Pabinger (Austria)**

Caesarean section or Vaginal delivery

**R. Ljung (Sweden)**

**16:00**

**End of the Congress**